The global Generic Oncology Drugs Market is witnessing significant growth due to the rising prevalence of various cancer types, including breast, lung, colorectal, and prostate cancers. Increasing demand for affordable and effective cancer treatments, along with frequent patent expirations of branded oncology drugs, is accelerating the shift toward generic alternatives. Governments and...

The US Oncology Drugs Market represents a major share of the global oncology industry, driven by extensive cancer research activities, strong pharmaceutical innovation, and high adoption of advanced treatment modalities. The country benefits from a large pipeline of investigational oncology drugs, robust clinical trial infrastructure, and significant investments in precision medicine and...

According to a new report from Intel Market Research, the global Brigatinib API market was valued at USD 42.5 million in 2025 and is projected to reach USD 89.7 million by 2034, growing at a robust CAGR of 8.1% during the forecast period (2026–2034). This growth is propelled by the increasing global incidence of non-small cell lung cancer, particularly ALK-positive cases among...

According to a new report from Intel Market Research, the global Crizotinib Drugs market was valued at USD 582.4 million in 2025 and is projected to reach USD 1,043.7 million by 2034, growing at a CAGR of 6.7% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of lung cancer, increasing adoption of molecular diagnostic testing for genetic...

According to a new report from Intel Market Research, the global Multi-target MET TKIs market was valued at USD 1.52 billion in 2025 and is projected to reach USD 3.18 billion by 2034, growing at a CAGR of 7.6% during the forecast period (2026–2034). This growth is propelled by the rising global incidence of non-small cell lung cancer and medullary thyroid cancer, precision oncology...

According to a new report from Intel Market Research, the global Selpercatinib Capsules market was valued at USD 420 million in 2025 and is projected to reach USD 820 million by 2034, growing at a CAGR of 7.8% during the forecast period (2026–2034). This growth is propelled by the increasing prevalence of RET-altered cancers, growing adoption of biomarker-driven therapies, and...

The Oncology Drugs Markets share is undergoing a dynamic transformation, with adult patients expected to represent a substantial portion of the market. By 2024, this demographic is projected to hold approximately 72% of the market share, reflecting an urgent need for effective cancer therapies tailored for older populations. A significant contributor to the Oncology Drugs Markets share is the...

According to a new report from Intel Market Research, the global TKIs for Breast Cancer market was valued at USD 1.82 billion in 2025 and is projected to reach USD 3.74 billion by 2034, growing at a CAGR of 7.3% during the forecast period (2025–2034). This growth is propelled by the rising global incidence of breast cancer, growing adoption of precision oncology, and increasing regulatory...